| abstract |
The present invention provides a compound of the formula (I) or (II, wherein R 1 is H, alkyl, alkenyl or aryl, R 2 is H, alkyl or aryl, R 3 is H, a alkyl, alkenyl or aryl, R 4 and R 4 -R 8 are independently R 10 , C(O)R 10 or SO 2 R 10 , wherein R 10 is H, alkyl, alkenyl or aryl, and R 9 is R 9a , C(O)R 9a or SO 2 R 9a , wherein R 9a is H, alkyl, alkenyl or aryl. R 9a can be unsubstituted or substituted with one or more oxo(═O), OR 9b , OC(O)R 9b , OSO 2 R 9b , NHR 9b , NHC(O)R 9b and NHSO 2 R 9b groups. R 9b is H, alkyl, alkenyl, or aryl. R 9b can be unsubstituted or substituted with one or more groups such as oxo(═O), OR 9c , CO 2 R 9c , CO 2 R 9c and OC(O)R 9c . R 9c is H, or a unsubstituted or substituted alkyl, alkenyl or aryl. The present invention further provides a composition comprising at least one compound of the present invention and a pharmaceutically acceptable carrier, alone or in combination with at least one additional active agent. The present invention further provides a method of treating a condition treatable by the inhibition of vacuolar-type (H+)-ATPase and a method of treating cancer. |